Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
- Cancer
- Concussions
- CRISPR
- Drug Pricing
- End of Life
- Health Disparities
- Immigration
- Opioids
- Trump
- Women’s Health
- Zika
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Finance

First Opinion

A new wave of pharma mergers could put innovative drugs in the pipeline

By Michael S. Ringel and Michael K. Choy

First Opinion

How Martin Shkreli used social media to fuel his short-selling shenanigans

By Steve Brozak

advertisement

Biotech

Are short sellers ruining biotech? That’s ‘hogwash,’ analysts say

By Damian Garde

advertisement

Pharmalot

Should drug makers be banned from buying back stock? Take our reader poll

By Ed Silverman

First Opinion

How much do doctors really make? Compare your salary to various specialties

By Zach Nayer

Biotech

Forget the science. These investors think they can pick biotech winners by algorithm

By Damian Garde

Pharmalot

Teamsters criticize McKesson for ‘excessive’ CEO pay and its role in the opioid crisis

By Ed Silverman

advertisement

First Opinion

More female leadership: a different kind of health care reform

By Annette Walker

advertisement

Health

The ice bucket challenge, made famous by ALS patient Pete Frates, raised millions. Here’s how the money was used

By Rebecca Robbins

Biotech

Before a biotech stock debacle, one Republican congressman made a prescient trade

By Damian Garde

Pharmalot

Pharma payments to U.K. docs and hospitals jumped 25 percent, but many docs balk at disclosure

By Ed Silverman

Pharmalot

Allergan to pay $13 million to settle whistleblower lawsuit over kickbacks

By Ed Silverman

Pharmalot

Doctors prescribed fewer meds after payments from pharma were disclosed

By Ed Silverman

Pharmalot

Pharmalittle: Sarepta gets a new CEO; IRS probes a charity backed by drug makers

By Ed Silverman

Biotech

New Sarepta CEO is top drug talent with coveted commercial expertise; sell-side ‘confidence’ cliche

By Adam Feuerstein

Exclusive

Top investor slashes Moderna’s valuation as company struggles to live up to its own hype

By Damian Garde

Pharmalot

What risk? Former Ariad employees are charged with insider trading

By Ed Silverman

Pharma

The FDA may move to shorten that grim list of side effects in every drug ad. Advertising execs can’t wait

By Megan Thielking

Biotech

Merck shocks with CETP cholesterol study win; Ra Pharma’s scant PNH data

By Adam Feuerstein

Biotech

This investor predicted the big biotech stock rally. And he thinks it has legs

By Adam Feuerstein

Biotech

Will Trump’s FDA relax standards for drug approval? We’ll get a clue soon with decision on Portola’s anticoagulant

By Adam Feuerstein

Biotech

Biotech stocks are soaring. Here are four reasons why

By Adam Feuerstein

Biotech

Camille Samuels: Favoring ‘new markets for unmet needs’

By Meghana Keshavan

Biotech

Biotech R&D costs are outpacing revenues, but funding is still strong, report says

By Meghana Keshavan

Biotech

How John Flannery recast GE Healthcare and its biologics business

By Karen Weintraub

Pharmalot

Advisory firm urges voting against Mylan board for destroying shareholder value

By Ed Silverman

Pharmalot

Pharmalittle: AstraZeneca worries over a setback, Roche encounters a hitch in the UK

By Ed Silverman

Pharma

Gilead’s HIV prevention pill will be going generic. How far will Teva drop the price?

By Rebecca Robbins

Business

Saying Los Angeles lacks a great cancer center, Soon-Shiong plans to open one

By Rebecca Robbins

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT